Skip to main content
OpenTrials
Completed

NCT Number: NCT02943915

The WISE Trial - Walking Improvement for SCI With Exoskeleton

A randomized, controlled trial comparing exoskeleton gait training with standard gait training or no gait training in community-dwelling participants with chronic incomplete spinal cord injury

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Injuries, Spinal Cord Central Nervous System Diseases Nervous System Diseases Spinal Cord Diseases Spinal Cord Injuries Trauma, Nervous System Wounds and Injuries

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

Loading trial locations.

About this study

Community dwelling iSCI participants may improve clinical gait function by engaging in a gait training regimen, where robotic exoskeletons can readily deliver a precise dose and simultaneously reduce the physical stress imposed on therapists using conventional manually assisted stepping practice. Exoskeleton training is predicted to improve function in participants receiving usual care, but not superior to intensity-matched manual training. The rationale to implement exoskeleton robotics as preference in gait training is based on precision dosing, over-ground training, and reduced therapist burden for high repetition training.

The investigators aim to demonstrate that Ekso exoskeleton training can significantly improve gait speed in stable chronic, community-dwelling incomplete SCI (iSCI) participants. The objectives of this study are the following:

A. Primary Objective:

To demonstrate that a 12 week robotic gait training regimen can lead to a clinically meaningful improvement in independent gait speed on the 10 Meter Walk Test (10MWT) in community dwelling participants with chronic iSCI.

B. Secondary Objectives:

  • To examine the economic factors such as number of physical therapists/staff required during training.
  • To analyze the physical burden on therapists assisting and supervising during training.
  • To study the influence of factors that may modify the gait recovery in the chronic incomplete SCI population (demographic, clinical, functional, psychological, balance, etc.).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Motor incomplete paraplegia or tetraplegia
  • Neurological level of injury (NLI) C1- approximately T10 (inclusive, for upper motor neuron injuries only), as determined by the International Standards for Neurological Classification of SCI (ISNCSCI)
  • Sufficient diaphragmatic strength such that respiration is not compromised with exercise.
  • Sufficient upper extremity strength to use a front wheeled walker either by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction/adduction and flexion/extension 4/5)
  • AIS-C SCI & AIS-D SCI, as determined by the International Standards for Neurological Classification of SCI (ISNCSCI)
  • Ambulates at <0.44 meters/second with or without physical assistance and assistance device
  • WISCI ≥ 1
  • 18 - 75 yrs, inclusive
  • No current or history of other neurological conditions
  • Screened and cleared by a physician
  • Involved in standing program or must be able to tolerate at least 15 min upright
  • Weigh 220 pounds (100kg) or less
  • Be able to fit into the Ekso device
  • Approximately between 5'0" and 6'4" tall
  • Standing hip width of approximately 18" or less
  • Have near normal range of motion in hips, knees and ankles

Exclusion criteria

  • AIS-A SCI or AIS-B SCI
  • Lower motor neuron injuries, as shown by absent reflexes during bilateral quadriceps and Achilles tendon taps
  • < 3 months since previous intensive gait training regimen
  • Already walking at self-selected ambulation speeds of at least 0.44 meter/second with or without assistance
  • Currently involved in another intervention study
  • Concurrent neurological disease
  • Hip flexion contracture greater than ~17°
  • Knee flexion contracture greater than 12°
  • Unable to achieve neutral ankle dorsiflexion with passive stretch (neutral with max 12° knee flexion)
  • Leg length discrepancy
  • Greater than 0.5" for upper leg
  • Greater than 0.75" for lower leg
  • Spinal instability
  • Unresolved deep vein thrombosis
  • Uncontrolled autonomic dysreflexia
  • Severe muscular or skeletal pain
  • Spasticity that prevents joint motion (severe stiffness or rigidity,) where both legs have a Modified Ashworth Score (MAS) score of 3 or higher for half or more of their proximal lower extremity muscles; proximal muscles include hip flexors/extensors/adductors and knee flexors/extensors.
  • Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness
  • Pregnancy
  • Cognitive impairments - unable to follow 2 steps commands and communicate for pain or to stop session
  • Shoulder extension Range of Motion (ROM) < 50° excludes crutches during sit to stand or vice versa. (Walking with crutches permitted.)
  • Participant requires the assistance of more than one therapist to transfer safely.
  • Uncontrolled or severe orthostatic hypotension that limits standing tolerance; defined as sustained, symptomatic drops in systolic and diastolic blood pressure when moving from sitting to standing
  • Active heterotrophic ossification (HO), hip dysplasia or hip/knee axis abnormalities
  • Colostomy
  • History of long bone fractures since the SCI, secondary to osteoporosis
  • Unable to sustain current medication regimen
  • Any reason the physician may deem as harmful to the participant to enroll or continue in the study

Treatment and study plan

Ekso GT Rehabilitation Therapy

Device

Walking Improvement for Spinal Cord Injuries with Exoskeleton

Other names: Exoskeleton

Body Weight Supported (BWS) Treadmill Training

Device

Standard gait training using BWS PT and overground training

Other names: Conventional Therapy

Primary outcomes

  1. Change in Gait Speed From Baseline to 12 Weeks Using 10 Meter Walk Test (10MWT)

    Time frame: Baseline and 12 Weeks

    The mean change in gait speed demonstrated during the 10MWT after 12 weeks of training and compared between groups. Positive values indicate improvement in gait speed (faster) from baseline to 12 weeks. Negative values indicate a reduction in gait speed (slower) from baseline to 12 weeks.

Secondary outcomes

  1. Number of Participants Who Met the Minimal Clinically Important Difference of 0.15m/s in Gait Speed Per 10 Meter Walk Test (10MWT) From Baseline to 24 Weeks

    Time frame: Between baseline and 24 weeks

    Number of participants who achieve the Minimal Clinically Important Difference (MCID) of 0.15 m/s during the 10MWT when comparing between baseline gait speed and gait speed at 24 weeks.

  2. Change in Distance Covered Over 6 Minutes From Baseline to 24 Weeks

    Time frame: Baseline-24 weeks

    6 minute walk test (6MWT) completed at baseline and 24 weeks. Change assessed. Positive values indicate an increase in distance was able to be walked at 24 weeks versus at baseline. Negative values indicate a decrease in distance was walked at 24 weeks versus at baseline.

  3. Change in Time Required to Complete Timed Up and Go (TUG) Test From Baseline to 24 Week Follow up

    Time frame: Baseline and 24 weeks

    Examined balance and walking in participants at baseline and follow up at 24 weeks. Positive values indicate an improvement of time (less time) required to complete task at 24 week follow up versus at baseline. Negative values indicate a decline, more time required to complete task at follow up versus baseline.

  4. Number of Participants Who Experienced a Fall During Protocol

    Time frame: Throughout 24 weeks

    At each training session, assessed if participant had experienced any falls. Count is number of participants who reported that yes, they did experience a fall.

  5. Change in Berg Balance Scale Score From Baseline to 24 Weeks

    Time frame: Baseline-24 weeks

    Measurement of static and dynamic sitting and standing balance completed at baseline and at 24 weeks. Berg balance scale is a 14 item test with each item scored from 0-4. Possible scores range from 0-56. Higher scores indicate a lower risk of falls and better balance. Positive numbers indicate an improvement in Berg balance scale (scored out of 56), meaning that the participant scored higher at 24 weeks than at baseline. Negative values indicate a decline in performance of the Berg balance scale (scored out of 56), meaning that the participant scored lower at 24 weeks than at baseline.

Sponsors and collaborators

Lead sponsor

Ekso Bionics

Industry

Collaborators

  • Burke Medical Research Institute

Registry information

Acronym: WISE

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Oct 25, 2016
Registry last updated
Oct 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.